Why Imunon, Inc.’s (IMNN) Stock Is Down 7.17%
As of Tuesday, June 03, Imunon, Inc.’s IMNN share price has dipped by 7.17%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Commentary & Analysis
Why Imunon, Inc.’s (IMNN) Stock Is Down 15.54%
As of Tuesday, June 03, Imunon, Inc.’s IMNN share price has dipped by 15.54%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Imunon, Inc.’s (IMNN) Stock Is Up 22.98%
As of Monday, June 02, Imunon, Inc.’s IMNN share price has surged by 22.98%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Imunon, Inc.’s (IMNN) Stock Is Up 13.55%
As of Monday, June 02, Imunon, Inc.’s IMNN share price has surged by 13.55%, which has investors questioning if this is right time to sell.Tudor Pop
Is Imunon Inc (IMNN) Stock a Good Investment?
Learn more about Imunon Inc's (IMNN) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | IMNN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.7 | $252.6 | 5% |
|
| Shares Out (Mil) | 5.0 | 52.3 | 14% |
|
| Institutional Ownership | 38.7% | 92.1% | 17% |
|
| Float (Mil) | 3.6 | 40.2 | 9% |
|
| Beta | 1.93 | 0.95 | 91% |
|
| Avg Daily Volume (000s) | 485 | 455 | 58% |
|
| Price Change (52-week) |
(76.0%) | 52.9% | 8% |
|
| Growth | IMNN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 7.6% | (9.9%) | 51% |
|
| EPS (5yr) | 44.7% | 16.0% | 91 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (53.5%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 3 | 4 | |
| Current EPS | ($0.910) | ($3.010) | ($2.183) | |
| Month Ago EPS | ($0.570) | ($2.525) | ($2.183) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.023) | ($3.330) | ($1.913) | |
| Year/Year Chg | 7.7% | (55.9%) | (71.2%) | |
| Financials | IMNN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($15) | ($43) | 26% |
|
| EPS (TTM) | ($4.792) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($31) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $5 | 15% |
|
| Enterprise Value (Q1) (Mil) | $4 | $180 | 5% |
|
| Valuation | IMNN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.85 | 2.56 | 48% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IMNN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (196.8%) | (49.8%) | 2% |
|
| ROE | (768.3%) | (55.5%) | 0% |
|
| Liabilities to Assets | 58.1% | 30.3% | 51% |
|
| F-Score | 1 | 3 | 1% |
|
Imunon, Inc. did not pass any screens on 7/31/2026.
